financetom
Business
financetom
/
Business
/
T Rowe's quarterly profit beats estimates on tailwinds from market rally
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
T Rowe's quarterly profit beats estimates on tailwinds from market rally
Apr 26, 2024 5:21 AM

(Reuters) - T Rowe Price's ( TROW ) first-quarter profit beat expectations as an upswing in markets boosted its assets under management and softened the hit from outflows, it said on Friday.

Asset managers have seen money leave their funds as high interest rates boost the appeal of safe-haven assets like cash. Some investors are also waiting for more certainty on the trajectory of interest rates before wading back into the market.

But assets under management, which determines the fees managers charge, have still grown due to an increase in the value of investments.

At the end of the quarter, T Rowe's AUM was $1.54 trillion, 15% higher than last year, despite $8 billion of net outflows.

"While outflows will persist in 2024, we continue to believe that there will be substantial improvement this year driven by higher sales and lower redemptions," CEO Rob Sharps said.

Investment advisory fees, typically a percentage of the AUM, rose nearly 12%, to $1.55 billion.

Profit rose 36%, to $573.8 million for the three months ended March 31. Excluding one-time costs, the company earned $2.38 per share versus an expectation of $2.04 per share, according to LSEG data.

Active managers like T Rowe buy and sell investments more frequently compared to passive fund managers.

Over the last several years, such companies have been ceding market share to low-cost passive funds, which can earn decent returns just by investing in the benchmark indexes or other passive vehicles, eliminating the need for active stock-picking.

But higher interest rates and market volatility could usher in a new era for active investing. Analysts believe investors will have to adopt a more hands-on strategy to add value to their portfolios and manage risk, in contrast to the set-and-forget approach that has defined investing over the past decade.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mistral AI raises 1.7 billion euros as ASML becomes its top shareholder
Mistral AI raises 1.7 billion euros as ASML becomes its top shareholder
Sep 8, 2025
AMSTERDAM, Sept 9 (Reuters) - French artificial intelligence startup Mistral AI has raised 1.7 billion euros ($2 billion) in its latest funding round led by Dutch chip equipment maker ASML, the companies said on Tuesday, confirming a Reuters report from Sunday. ASML is investing 1.3 billion euros in Mistral AI as part of a series C funding round, making it...
Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion
Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion
Sep 8, 2025
BERLIN, Sept 9 (Reuters) - Switzerland's Novartis will acquire Tourmaline Bio ( TRML ) with an offer price of $48 per share, in a deal valuing the New York-based company at $1.4 billion on a fully diluted basis, it said on Tuesday. Novartis said it expected the deal to close in the fourth quarter and for Tourmaline to become an...
Sam Altman-Founded Project's World Token Soars 47%: Here's Why Its Moving
Sam Altman-Founded Project's World Token Soars 47%: Here's Why Its Moving
Sep 8, 2025
World (CRYPTO: WLD) token defied gravity on Monday after a Nasdaq-listed firm embraced it as its primary treasury reserve asset. WLD Token Lifts Crypto Market WLD, the native currency of the Sam Altman-founded identity verification project, boomed nearly 48% in the last 24 hours, becoming the second-highest gainer among coins with a market value greater than $1 billion. The coin...
BRIEF-Novartis To Buy Tourmaline Bio
BRIEF-Novartis To Buy Tourmaline Bio
Sep 8, 2025
Sept 9 (Reuters) - NOVARTIS AG: * TO ACQUIRE TOURMALINE BIO, COMPLEMENTING CARDIOVASCULAR PIPELINE WITH PACIBEKITUG FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) * OFFER PRICE USD 48 PER SHARE, COMPANY VALUED AT USD 1.4BN * EXPECTS TO MERGE ACQUIRING SUBSIDIARY WITH AND INTO TOURMALINE * TRANSACTION IS EXPECTED TO CLOSE IN Q4 OF 2025 Source text: Further company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved